DMPK (drug metabolism and pharmacokinetics) issues remain one of the major reasons for compound attrition in the clinic. To avoid expensive product development failures, it is important to incorporate DMPK assessment into early stages of drug discovery process. DMPK support of safety and toxicology programs during the drug development stages is equally important since the link between the compound exposure and toxicological effects needs to be demonstrated. Finally, DMPK tools such as pharmacokinetics (PK) modeling and simulation allow for the prediction of human PK and the estimation of an efficacious dose in humans.
DMPK4BIOTECH provides DMPK consulting for biotech companies. It is run by Masha Sergeeva, PhD, a DMPK expert with more than 20 years of experience in industry and academia. The Company offers advice on drug metabolism, pharmacokinetics and bioanalysis, supports safety and toxicology studies, oversees IND-enabling programs, helps with IND filing, performs clinical PK analysis, modeling and simulation.